Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …

Immunotherapy is a promising area of therapy in patients with neuro-oncological malignancies.
However, early-phase studies show unique challenges associated with the assessment …

A recent joint meeting was held on January 30, 2014, with the US Food and Drug
Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, …

Although machine learning (ML) has shown promise across disciplines, out-of-sample
generalizability is concerning. This is currently addressed by sharing multi-site data, but such …

Purpose Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1 R132MUT) is frequent
in low-grade diffuse gliomas and, within glioblastoma (GBM), has been proposed as a …

Radiographic endpoints including response and progression are important for the evaluation
of new glioblastoma therapies. The current RANO criteria was developed to overcome …

Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and
have shown preliminary clinical activity against mIDH glioma. We evaluated both agents in a …

PURPOSE Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs)
and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is …

Purpose: To present comprehensive examinations of the assumptions made in functional
diffusion map (fDM) analyses and provide a biological basis for fDM classification. Materials …

Purpose: Lower grade gliomas (LGGs) are malignant brain tumors. Current therapy is associated
with short- and long-term toxicity. Progression to higher tumor grade is associated with …